This study focuses on individuals with Metastatic hormone sensitive prostate cancer, a type of prostate cancer that has spread to other parts of the body and is still responsive to hormone treatments. Participants in the study are currently receiving androgen deprivation therapy, which is a method used to lower the levels of male hormones to help slow the growth of cancer cells. The purpose of the study is to determine if adding new treatments to the standard care can improve survival and cancer outcomes.

One of the treatments being tested is lutetium (177lu) vipivotide tetraxetan, which is administered as a solution for injection or infusion directly into a vein. This medication is a type of radiopharmaceutical, meaning it contains a small amount of radiation designed to target cancer cells. The study follows a specific design to compare different treatment approaches against standard care to see which options are most effective for patients.